Anaconda Biomed S.L. Secures €20 Million Round of Funding

Anaconda Biomed获2000万欧元融资,推进缺血性卒中血管内治疗研究

2019-12-05 17:00:11 BioSpace

本文共1561个字,阅读需4分钟

“With this new round of funding, we will be able to advance our work in developing and testing next-generation technology that has the potential to dramatically accelerate and improve endovascular treatment of major ischemic stroke patients,” stated Francois Salmon, CEO of Anaconda Biomed S.L. “This financial backing is further validation that the lifesaving work we are engaged in at Anaconda is absolutely vital in the quest to reduce the incidence of death and disability following a stroke.” Finding new and more effective treatments for the onset of stroke remains a medical priority for the healthcare industry. According to the Lancet, stroke is the second leading cause of death worldwide, with 5.5 million deaths attributed to this cause in 2016. A New England Journal of Medicine report from the Global Burden of Disease (GBD) 2016 Lifetime Risk of Stroke Collaborators stated that the estimated global lifetime risk of stroke in 2016 for those aged 25 years or older was 24.9 percent, an increase from 22.8 percent in 1990. Barcelona, Spain-based venture capital firm Asabys Partners led the round from its fund, Sabadell Asabys Health Innovation Investments SCR, SA, with participation from existing investors Ysios Capital, Omega Funds and Innogest, as well as Sabadell Venture Capital, who joined the previous financing round. “For Asabys Partners, this investment in Anaconda is a confirmation of our investment strategy, which is focused on pushing the boundaries of science and technology with the goal of addressing some of today’s most challenging medical issues,” said Josep Ll. Sanfeliu, co-founder of Asabys Partners. Sylvain Sachot, investment director of Asabys Partners, added, “We believe that Anaconda will bring a cutting-edge thrombectomy system to the market that will effectively treat one of the leading causes of death and incapacity in the world today.” Anaconda’s Advanced Thrombectomy System consists of a delivery catheter, a unique, funnel-shaped aspiration catheter and a stent retriever. When deployed, the funnel self-expands and directly conforms to the artery diameter up to 5mm, locally arresting flow and allowing full thrombus extraction without fragmentation. The system is designed to deliver significant improvement in revascularization rates at both first and third pass. Anaconda Biomed S.L. has already enrolled 14 patients in a 125-patient first-in-human study, with results to be used to support a regulatory submission to the U.S. Food and Drug Administration. About Asabys Partners Sabadell Asabys Health Innovation Investments SCR, SA is a venture capital vehicle managed by Asabys Partners, a firm founded by Josep Ll. Sanfeliu and Clara Campàs. Sabadell Asabys Health Innovation Investments is backed by Banc Sabadell as anchor investor and has a target size of over 80 million euros, aiming to invest in 12 companies in the next years. Asabys was founded in 2018 and started operations in 2019. Asabys is focused on medtech, digital therapeutics, and early stage biopharma, supporting highly innovative and transformative technologies. Since its inception, Asabys Partners has invested in Psious, a digital mental health company, also invested in the early stage biotech company Ona Therapeutics, and recently in the Berlin-based digital therapeutics company, Care Care, in the area of gastrointestinal diseases in co-investment with Johnson & Johnson. For more information, visit www.asabys.com. About Anaconda Biomed S.L. Anaconda Biomed S.L. is a medical technology company dedicated to developing next generation thrombectomy systems for the treatment of ischemic stroke. Its flagship product is the Advanced Thrombectomy System.
“有了新一轮的资金,我们将能够推进我们开发和测试下一代技术的工作,这项技术有可能显著加快和改善主要缺血性脑卒中患者的血管内治疗,” Francois Salmon 说。Anaconda Biomed S.L .的首席执行官说:“这一财政支持进一步证实,我们在 Anaconda 从事的救生工作对于减少中风后死亡和残疾的发生率至关重要。” 寻找新的和更有效的治疗中风仍然是医疗行业的优先事项。据《柳叶刀》报道,中风是全球第二主要原因,2016年有550万人死于中风。《新英格兰医学杂志》( New England Journal of Medicine )发布的《2016年全球疾病负担( GBD )卒中合作者的终身风险报告》指出,2016年,25岁或25岁以上人群卒中的全球寿命风险估计为24.9%,高于1990年的22.8%。 总部位于西班牙巴塞罗那的风险投资公司 Asabys Partners 从其基金 Sabadell Asabys Health Innovation Investments SCR , SA 主导了这轮融资,现有投资者 Ysios Capital 、 Omega Funds 和 Innovgest 以及 Sabadell Venture Capital 参与了前一轮融资。 “对 Asabys Partners 而言,此次对 Anaconda 的投资证实了我们的投资战略,该战略的重点是推进科技领域的边界,以解决当今一些最具挑战性的医疗问题,” Josep L 表示。Asabys Partners 联合创始人 Sanfeliu 。 Asabys Partners 的投资总监 Sylvain Sacht 补充道:“我们相信, Anaconda 将为市场带来一种尖端的血栓切除术系统,这将有效地治疗当今世界主要的死亡和无能原因之一。” Anaconda 的高级血栓成形术系统包括一种输送导管、一种独特的漏斗式导尿管和一种支架拾取器。当部署时,漏斗会自我膨胀,并直接符合动脉直径5毫米,局部阻塞流,并允许全血栓提取不破碎。该系统的目的是提供显着改善血运重建速度在第一和第三次通过。 Anaconda Biomed S.L .公司已经将14名患者纳入了一项125名患者的首次人体试验,其结果将用于支持向美国食品药品监督管理局(Food and Drug Administration)提交的法规。 关于 Asabys 合作伙伴 SabadelAsabys Health Innovation Investments SCR , SA 是由 Joshep L .创立的 Asabys Partners 管理的风险投资工具。Sanfeliu 和 Clara Camp à s 。Sabadell Asabys Health Innovation Investments 由 Sabadell 银行作为主要投资者提供支持,目标规模超过8000万欧元,计划在未来几年投资12家公司。 Asabys 成立于2018年,于2019年开始运营。Asabys 专注于医疗技术、数字治疗和早期生物制药,支持高度创新和转化技术。Asabys Partners 自成立以来,投资了一家数字精神健康公司 Psous ,也投资了早期生物技术公司 Ona Therapeutics ,最近又投资了总部位于柏林的数字治疗公司 Care Care ,在胃肠疾病领域与强生共同投资。有关详细信息,请访问 www.asabys.com 。 关于 Anaconda Biomed S.L . Anaconda Biomed S.L .是一家致力于开发下一代血栓切除术系统治疗缺血性中风的医疗技术公司。其旗舰产品是先进的血栓切除术系统。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文